# Study to Assess the Safety and Immunogenicity of GSK Meningococcal Group B Vaccine When Administered Concomitantly With GSK Meningococcal MenACWY Conjugate Vaccine in Healthy Subjects of 16-18 Years of Age

> **NCT04318548** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 945 (actual)

## Conditions studied

- Infections, Meningococcal

## Interventions

- **COMBINATION_PRODUCT:** Meningococcal Group B Vaccine (GSK3536829A) (rMenB+OMV NZ)
- **BIOLOGICAL:** Meningococcal MenACWY Conjugate Vaccine (GSK3536820A) (MenA lyo + MenCWY liquid)
- **COMBINATION_PRODUCT:** Placebo

## Key facts

- **NCT ID:** NCT04318548
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-25
- **Primary completion:** 2023-11-21
- **Final completion:** 2023-11-21
- **Target enrollment:** 945 (ACTUAL)
- **Last updated:** 2025-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04318548

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04318548, "Study to Assess the Safety and Immunogenicity of GSK Meningococcal Group B Vaccine When Administered Concomitantly With GSK Meningococcal MenACWY Conjugate Vaccine in Healthy Subjects of 16-18 Years of Age". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04318548. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*